作者
Benjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan-Birsoy, Gary A Ulaner, Michael Walsh, Mariko Yabe, Kseniya Petrova-Drus, Maria E Arcila, Marc Ladanyi, David B Solit, Michael F Berger, David M Hyman, Mario E Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J Dunkel, Vicente Santa-María López, Jaume Mora, Julien Haroche, Jean-Francois Emile, Olivier Decaux, Frederic Geissmann, Savvas N Savvides, Alexander Drilon, Eli L Diamond, Omar Abdel-Wahab
发表日期
2019/12
期刊
Nature medicine
卷号
25
期号
12
页码范围
1839-1842
出版商
Nature Publishing Group US
简介
Histiocytoses are clonal hematopoietic disorders frequently driven by mutations mapping to the BRAF and MEK1 and MEK2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in patients with histiocytosis.
学术搜索中的文章
BH Durham, E Lopez Rodrigo, J Picarsic, D Abramson… - Nature medicine, 2019